ADA: Once-Daily Semaglutide Superior for Reduction in Body Weight
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, June 27, 2023 -- Oral semaglutide 50 mg once daily leads to a superior and clinically meaningful reduction in body weight for adults with overweight or obesity without type 2 diabetes, according to a study published online June 25 in The Lancet to coincide with the annual meeting of the American Diabetes Association, held from June 23 to 26 in San Diego.
Filip K. Knop, M.D., from the University of Copenhagen in Denmark, and colleagues conducted a randomized, phase 3 superiority trial involving adults with a body mass index of at least 30 kg/m2 or at least 27 kg/m2 with bodyweight-related complications and comorbidities, without type 2 diabetes, in a trial conducted at 50 outpatient clinics in nine countries. A total of 667 participants were randomly assigned to oral semaglutide 50 mg or placebo (334 or 333, respectively) once per day for 68 weeks, plus lifestyle intervention.
The researchers found that from baseline to week 68, the estimated mean bodyweight change was −15.1 and −2.4 percent with semaglutide and placebo, respectively. Compared with placebo, in the semaglutide group, more participants reached bodyweight reductions of at least 5 percent (85 versus 26 percent; odds ratio, 12.6), 10 percent (69 versus 12 percent; odds ratio, 14.7); 15 percent (54 versus 6 percent; odds ratio, 17.9), and 20 percent (34 versus 3 percent; odds ratio, 18.5).
"These results indicate that oral semaglutide 50 mg could provide an effective, future option for people with overweight or obesity who would benefit from a glucagon-like peptide-1 receptor agonist," the authors write.
Several authors disclosed ties to pharmaceutical companies, including Novo Nordisk, which manufactures semaglutide and funded the study.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2023
Read this next
GLP-1 Receptor Agonist Dispensing Up From 2020 to 2023 for Teens, Young Adults
WEDNESDAY, May 22, 2024 -- For adolescents and young adults, glucagon-like peptide-1 receptor agonist (GLP-1 RA) dispensing increased from 2020 to 2023, according to a research...
Ultraprocessed Foods Increase Adiposity, Cardiometabolic Risk in Children
WEDNESDAY, May 22, 2024 -- High ultraprocessed food (UPF) consumption in young children is associated with adiposity and other cardiometabolic risk factors, according to a study...
Sleep Restriction Tied to Negative Cognitive Effects in Teens With Overweight, Obesity
WEDNESDAY, May 22, 2024 -- Adolescents with overweight or obesity may be more vulnerable to negative cognitive effects following sleep restriction, according to a study published...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.